Introduction
The Ryanodine Receptor 1 (RyR1) is a critical calcium release channel in skeletal muscle. Mutations in RyR1 can lead to Malignant Hyperthermia (MH), a life-threatening condition where volatile anesthetics trigger uncontrolled calcium release, causing muscle rigidity and hyperthermia. While dantrolene has been the gold-standard treatment for MH for decades, its precise binding site and inhibitory mechanism remained elusive. This study utilizes high-resolution cryo-electron microscopy (cryo-EM) to define the structural basis of dantrolene action and uncovers a novel metabolic sensing role for the RY12 domain.
Methodology
Researchers employed single-particle cryo-EM to visualize RyR1 in various ligand-bound states, achieving resolutions between 2.2 Å and 2.6 Å through local refinement of peripheral domains. These structural findings were validated using planar lipid bilayer recordings to measure channel open probability ($P_o$) and site-directed mutagenesis (specifically the W882A mutation) to confirm the functional relevance of the identified binding pockets.
Results
The Dantrolene Binding Site and RY12 Domain
The study reveals that dantrolene does not bind to RyR1 in isolation but rather forms a ternary complex, stacking directly against a molecule of ATP or ADP within the RY12 domain. This "sandwich" arrangement is essential; functional assays demonstrated that dantrolene inhibition is strictly dependent on the presence of these nucleotides.
The binding induces a conformational change in the RY12 domain, which acts as a molecular clamp. This movement is allosterically coupled to the closure of the central pore, effectively shutting down the "leaky" channel characteristic of MH. Key residues, such as W882 and W996, were identified as critical for stabilizing this drug-nucleotide interaction. The W882A mutation was shown to completely abolish the inhibitory effect of dantrolene, providing functional confirmation of the structural model.
RY12 as a Metabolic Sensor
Beyond its role as a drug target, the RY12 domain was found to selectively bind two ADP molecules in the absence of dantrolene. This suggests that the domain functions as a natural sensor for the cellular ATP/ADP ratio. In conditions of metabolic stress or muscle fatigue where ADP levels rise, this site binds ADP to dampen RyR1 activity, serving as a "metabolic brake" to preserve cellular energy.
Mechanisms of MH Triggers
The researchers also mapped the binding sites for 4-chloro-m-cresol (4CmC), a known MH trigger. 4CmC was found to occupy "cryptic" pockets within the core solenoid and transmembrane domains. These sites are typically hidden, suggesting that the channel must undergo specific conformational shifts to allow trigger agents to access these pockets and activate the receptor.
Conclusion
By providing an atomic-level blueprint of the dantrolene binding site, this research resolves a long-standing mystery in muscle pharmacology. The discovery of the RY12 domain's dual role as a therapeutic target and a metabolic sensor opens new avenues for understanding muscle physiology and developing treatments for other RyR-related disorders, such as heart failure. Future work will focus on detailing the full mechanical pathway of allosteric signal transmission from the peripheral RY12 domain to the central pore.
Summary updated